LUCA Science is a pre-clinical stage biotechnology company that develops functional mitochondria as therapeutic agents to treat damaged tissues and organs. The company utilizes a proprietary method to isolate functional mitochondria, combining it with advanced drug delivery and formulation technology to create storable biopharmaceutical agents.
Subscribe to see LUCA Science’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
LUCA Science is a drug discovery company headquartered in Japan. It has raised at least $40.1M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $30.3M in June 2022. Xcout tracks 9 named people at LUCA Science, including Stig Ogata (President and Representative Director).
As of 16 November 2026. Source: Xcout Intel.
3 more named people on record for LUCA Science, with roles, board committees and tenure — see the full roster →
At least $40.1M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $30.3M | 11 named | |
| — | $9.8M | 10 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A funding-flow diagram of the 12 named investors across 2 rounds: who backed which round, who led it, and who came back for the next one.
Sign in to see it, or subscribe for the full funding history →
A few of LUCA Science's closest competitors — see the full list of competitors and alternatives →
Mighty Therapeutics, formerly known as Stealth BioTherapeutics, focuses on mitochondrial medicine. The company targets mitochondrial dysfunction associated with rare genetic mitochondrial diseases and common diseases of aging through targeted scientific research and treatment development.
Sarcomatrix Therapeutics Corp. is a biopharmaceutical and biotechnology research company headquartered in Reno, Nevada. The company is dedicated to pioneering muscle regeneration therapies and advancing novel therapeutics to treat muscle-wasting diseases.
Glycomine, Inc. is a biotherapeutics company focused on developing replacement therapies and treatments for serious rare genetic diseases, operating out of major life science hubs in San Francisco and Boston.
Retro Biosciences is a biotechnology research company based in Redwood City, California, that develops therapies targeting aging biology. Its goal is to extend healthy human lifespan by 10 years.
iRegene Therapeutics is a biotechnology company headquartered in Wuhan, China, with additional facilities in Suzhou. The firm specializes in regenerative medicine and advanced cell therapies designed to redefine modern medicine.
Immitra Bio GmbH is a biotechnology startup and ETH Zürich spin-off developing a scalable in-vivo genetic medicine platform to treat rare genetic diseases. Headquartered in Schlieren, Switzerland, the company secured early-stage venture funding to advance its gene-editing therapies.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about LUCA Science? Suggest a correction · Work at LUCA Science? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.